Clinical Applications of Neurotransmitter-Receptor Studies in Geriatric Neuropharmacology

Acta Medica Okayama

Volumn 50, Issue 4, 1996, Pages 173-190

  Gómez Vargas, Marvin ^a   Ogawa, Norio ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Aging; Neurodegenerative diseases; Neuropharmacology; Neurotransmitters; Receptor binding

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; FREE RADICAL; NEUROTRANSMITTER RECEPTOR; NOOTROPIC AGENT;

AGED; AGING; ALZHEIMER DISEASE; DRUG ANTAGONISM; DRUG EFFECT; ESTROGEN THERAPY; HUMAN; LEARNING; MEMORY; MEMORY DISORDER; MENTAL DISEASE; METABOLISM; NERVOUS SYSTEM; NEUROLOGIC DISEASE; PHYSIOLOGY; REVIEW;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTI-INFLAMMATORY AGENTS; ESTROGEN REPLACEMENT THERAPY; FREE RADICALS; HUMANS; LEARNING; MEMORY; MEMORY DISORDERS; MENTAL DISORDERS; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; NOOTROPIC AGENTS; RECEPTORS, NEUROTRANSMITTER;

EID: 0030203420     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. Hökfelt T, Johansson O, Ljungdable, Å, Lundberg JM and Schultzberg M: Peptidergic neurones. Nature (1980) 284, 515-521.
2. Ogawa N and Nukina I: Dopamine receptors in the central nervous system. Jpn J Neuropsychopharmacol (1983) 5, 897-905.
3. Snyder SH and Yamamura HI: Antidepressants and muscarinic acetylcholine receptors. Arch Gen Psychiatry (1977) 34, 236-239.
4. Ogawa N, Yamawaki Y, Kuroda H, Nukina I, Ota Z, Fujino M and Yanaihara N: Characteristics of thyrotropin releasing hormone (TRH) receptors in rat brain. Peptides (1982) 3, 669-677.
5. Snyder SH and Bennett JP: Neurotransmitter receptors in the brain: Biochemical identification. Ann Rev Physiol (1976) 38, 153-175.
6. Ogawa N, Mizuno S, Nukina I, Tsukamoto S and Mori A: Chronic thyrotropin releasing hormone (TRH) administration on TRH receptors and muscarinic cholinergic receptors in CNS. Brain Res (1983) 263, 348-350.
7. Bartus RT, Dean III RL, Beer B and Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 217, 408 -417.
8. Squire LR: Physostigmine: Effects on retention at different time after brief training. Psychon Sci. (1970) 19, 49-50.
9. Drachman DA and Leavitt J: Human memory and the cholinergic system: A relationship to aging. Arch Neurol (1974) 30, 113-121.
10. Bartus RT and Johnson HR: Short term memory in the rhesus monkey: Disruption from the anticholinergic scopolamine. Pharmacol Biochem Behav (1976) 5, 39-46.
11. Davies P and Mahoney AJF: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet (1976) 2, 1403.
12. Perry EK, Perry LH, Biessed G and Tomlinson BE: Necropsy evidence of central cholinergic deficits in senile dementia. Lancet (1977) 1, 189.
13. Coyle JJ, Price DL and Delong MR: Alzheimer's disease: A disorder of cortical cholinergic innervation. Science (1983) 219, 1184-1190.
14. Eckerman DA, Gordon WA, Edwards JD, McPhail RL and Gage MF: Effects of scopolamine and amphetamine on the radial maze performance in the rat. Pharmacol Biochem Behav (1979) 12, 545-602.
15. Okaichi H and Jarrad LE: Scopolamine impairs performance of a place and cut task in rats. Behav Neurol Biol (1982) 35, 319-325.
16. Deutch JA: The cholinergic synapse and the site of memory. Science (1971) 174, 788-794.
17. Buresova O and Bures J: Radial maze as tool for assessing the effect of drugs on the working memory of rats. Psychopharmacology (1982) 77, 268-271.
18. Stevens R: Scopolamine impairs spatial maze performance in rats. Physiol Behav (1981) 27, 385-386.
19. Watts J, Stevens R and Robinson C: Effects of scopolamine on radial maze performance in rats. Physiol Behav (1981) 26, 845-851.
20. Ogawa N, Mizukawa K, Haba K, Asanuma M and Mori A: Effects of chronic bifemelane hydrochloride administration on receptors for N-methyl-D-aspartate in the aged-rat brain. Neurochem Res (1992) 17, 689-691.
21. Ogawa IM, Mizukawa K, Haba K, Asanuma M and Mori A: Chronic bifemelane hydrochloride administration enhances muscarinic cholinergic receptor-binding in the senescent rat brain. J Med (1991) 22, 17 -27.
22. Ogawa N, Haba K, Yoshikawa H, Ono T and Mizukawa K: Comparison of the effects of bifemelane hydrochloride, idebenone and indeloxazine hydrochloride on ischemia-induced depletion of brain acetylcholine levels in gerbils. Res Commun Chem Pathol Pharmacol (1988) 61, 285-288.
23. Yamamoto M and Shimizu M: Effects of indeloxazine hydrochloride (YM-08054) on anoxia. Arch Int Pharmacodyn Ther (1987) 286, 272-281.
24. Tachikawa S, Harada M and Maeno H: Pharmacological and biochemical studies on a new compound, 2-(7-indenyloxymethyl) morpholine hydrochloride (YM-08054-1), and its derivatives with potential antidepressant properties. Arch Int Pharmacodyn Ther (1979) 238, 815-95.
25. Yamamoto M and Shimizu M: Cerebral activating properties of indeloxazine hydrochloride. Neuropharmacology (1987) 26, 761-770.
26. Tobe A, Egawa M and Nagai R: Effect of 4-(o-benzylphenoxyl-N-methyl amine hydrochloride (MCI-20160) on the scopolamine -induced deficit of spontaneous alteration behaviour in rats. Jpn J Pharmacol (1983) 33, 775-786.
27. Tobe A, Yamaguchi T, Nagai R and Egawa M: Effects of bifemelane hydrochloride (MCI-2016) on experimental amsesia (passive avoidance failure) in rodents. Jpn J Pharmacol (1985) 39, 153-161.
28. Higashida A and Ogawa N: Differences in the acquisition process and the effect of scopolamine on radial maze performance in three strains of rats. Pharmacol Biochem Behav (1987) 27, 483-489.
29. Ogawa N, Haba K, Sora YH, Higasida A, Sato H and Ogawa S: Comparison of the effects of bifemelane hydrochloride and indeloxazine hydrochoride on scopolamine-induced impairment in radial maze performance. Clin Ther (1988) 10, 704-711.
30. Olton DS and Samuelson RJ: Remembrance of places passed: Spatial memory in rats. J Exp Psychol (Anim Behav) (1976) 2, 97-116.
31. Wirsching BA, Beninger RJ, Jhamandas K, Boegman RJ and EI Defrawy SR: Differential effects of scopolamine on working and reference memory of rats in the radial maze. Pharmacol Biochem Behav (1984) 20, 659-662.
32. Jarrard LE, Kant GJ, Meyerhoff JL and Levy A: Behavioral and neurochemical effects of intraventricular AF64A administration in rats. Pharmacol Biochem Behav (1984) 21, 273-280.
33. Walsh TJ, Tilson HA, DeHaven DL, Mailman RB, Fisher A and Hanin I: AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long term passive avoidance and radial maze deficits in the rat. Brain Res (1984) 321, 91-102.
34. Jarrard LE: Selective hippocampal lesions and behavior: Effects of kinic acid lesions on performance of place and cue tasks. Behav Neurosci (1983) 97, 873-889.
35. Fontana DJ, Inouye GT and Johnson RM: Linopirdine (Dup 996) improves performance in several tests of learning by modulation of cholinergic neurotransmission. Pharmacol Biochem Behav (1994) 49, 1075-1082.
36. Dent GW, Rule BL, Tam SW and De Souza EB: Effects of the memory enhancer linopirdine (Dup 996) on cerebral glucose metabolism in naive and hypoxia-exposed rats. Brain Res (1993) 620, 7-15.
37. Aubert I, Rowe W, Meaney MJ, Gauthier S and Quirion R: Cholinergic markers in aged cognitively impaired Long-Evans rats. Neuroscience (1995) 67, 277-292.
38. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S and Quirion R: Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem (1992) 58, 529-541.
39. Quirion R, Wilson A, Rowe W, Aubert I, Richard J, Doods H, Parent A, White N and Meaney MJ: Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired rats. J Neurosci (1995) 15, 1455-1462.
40. Nabeshima T, Nitta A, Fuji K, Kameyama T and Hasegawa T: Oral administration of NGF synthesis stimulators reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats. Gerontology (1994) 40 (Suppl. 2), 46-56.
41. Foreman PJ, Perez-Polo JR, Angelucci L, Ramacci MT and Tagliatela G: Effects of acetyl-L-carnitine treatment and stress exposure on the nerve growth factor receptor (p75NGFR) mRNA level in the central nervous system of aged rats. Prog Neuropsychopharmacol Biol Psychiatry (1995) 19, 117-133.
42. Consolo S, Arnaboldi S, Giorgi S, Russi G and Ladinsky H: 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. NeuroReport (1994) 5, 1230-1232.
43. Early B, Burke M, Leonard BE, Gouret CJ and Junien JL: Evidence for an anti-amnesic effect of JO 1784 in the rat: A potent and selective ligand for the sigma receptor. Brain Res (1991) 546, 282-286.
44. Bronzetti E, Caporali MG, Felici L, Niglio T, Scotti de Carolis A and Amenta F: Muscarinic cholinoceptor subtypes in the rat frontoparietal cortex and ipsilateral lesions of the nucleus basalis magnocellularis. Pharmacology (1993) 46, 301-307.
45. Earley B, Burke M and Leonard BE: Behavioural, biochemical and histological effects of trimethyltin (TMT) induced brain damage in the rat. Neurochem Int (1992) 21, 351-366.
46. Early B, Biegon A and Leonard BE: Quantitative autoradiographic analysis of muscarinic receptors and quantitative histochemistry of acetylcholinesterase in the rat brain after trimethyltin intoxication. Neurochem Int (198) 15, 475-483.
47. Early B, Glennon M, Leonard BE and Junien JL: Effects of JO 1784, a selective sigma ligand, on the autoradiographic localization of M1 and M2 muscarinic receptor subtypes in trimethyltin treated rats. Neurochem Int (1995) 26, 559-570.
48. Decker MW: The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res Rev (1987) 12, 423-438.
49. Smith TD, Gallagher M and Leslie FM: Cholinergic binding sites in rat brain: Analysis by age and cognitive status. Neurobiol Aging (1995) 16, 161-173.
50. Consolo S, Wang JX, Fiorentin F, Vezzani A and Ladinsky H: In vivo and in vitro studies on the regulation of chlinergic neurotransmission in striatum, hippocampus and cortex of aged rats. Brain Res (1986) 374, 212-218.
51. Meek JL, Bertilsson L, Cheney DL, Zsilla G and Costa E: Aging induced changes in acetylcholine and serotonin content of discrete brain nuclei. J Gerontol (1977) 32, 129-131.
52. Tanaka K, Ogawa N, Asanuma M, Kondo Y and Mori A: Chronic administration of acetylcholinesterase inhibitor in the senescent rat brain. Neurobiol Aging (1994) 15, 721-725.
53. Noda Y, McGeer PL and McGeer EG: Lipid peroxides in brain during aging and vitamin E deficiency: Possible relations to changes in neurotransmitter indices. Neurobiol Aging (1982) 3, 173-178.
54. Springer JE, Tayrein MW and Loy R: Regional analysis of age-related changes in the cholinergic system of the hippocampal formation and basal forebrain of the rat. Brain Res (1987) 407, 180-184.
55. Lippa AS, Pelham RW, Beer BC, Critchett DJ, Dean RL and Bartus RT: Brain cholinergic dysfunction and memory in aged rats. Neurobiol Aging (1980) 1, 13-19.
56. Norman AB, Blaker SN, Thal L and Creese I: Effects of aging and cholinergic deafferentiation on putative muscarinic cholinergic receptor subtypes in rat cerebral cortex. Neurosci Lett (1986) 70, 289-294.
57. Leong SF, Lai JCK, Lim L and Clark JB: Energy metabolising enzymes in brain regions of adult and aging rats. J Neurochem (1981) 37, 1548-1556.
58. Markman MH, Ahn HS, Thal LJ, Sahrpless NS, Dvorkin B, Horowitz SG and Rosenfeld M: Evidence for selective loss of brain dopamine- and histamine-stimulated adenylate cyclase activities in rabbits with aging. Brain Res (1980) 192, 177-183.
59. McGeer EG and McGeer PL: Neurotransmitter metabolism in the aging brain.; in Neurobiology of Aging, Terry RD and Gershon S eds, Raven, New York (1976) pp389-403.
60. Ogawa N, Nomura M, Haba k, Asanuma M, Tanaka K, Hori K and Mori A: Effects of dihydroergotoxine on central cholinergic neuronal systems and discrimination learning test in aged rats. Brain Res (1992) 586, 229-234.
61. Ogawa N, Asanuma M, Hirata H, Kondo Y, Kawada Y and Mori A: Cholinergic deficits in aged rat brain are corrected with nicergoline. Arch Gerontol Geriatr (1993) 16, 103-110.
62. Asanuma M, Ogawa N, Kondo Y, Hirata H and Mori A: Effects of repeated administration of rolipram, a cAMP- specific phosphodiesterase inhibitor, on acetylcholinergic indices in the aged rat brain. Arch Gerontol Geriatr (1993)16, 191-198.
63. Schulz DW, Kuchel GA and Zigmond RE: Decline in response to nicotine in aged rat striatum: Correlation with a decrease in a subpopulation of nicotinic receptors. J Neurochem (1993) 61, 2225-2232.
64. Arendash GW, Sengstock GJ, Sanberg PR and Kem WR: Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res (1995) 674, 252-259.
65. 3H] -glutamate binding. J Neurochem (1987) 48, 543-551.
66. 3H] MK-801 binding to human hippocampal NMDA receptors. NeuroReport (1994) 5, 1237-1240.
67. Marczynski TJ, Artwohl J and Marczynska B: Chronic administration of flumazenil increases life span and protects rats from age-related loss of cognitive functions: A benzodiazepine/GABAergic hypothesis of brain aging. Neurobiol Aging (1994) 15, 69-84.
68. Abdulla FA, Abu-Bakra MA, Calamicini MR, Stephenson JD and Sinden JD: Importance of forebrain cholinergic and GABAergic systems to the age-related deficits in water maze performance of rats. Neurobiol Aging (1995) 16, 41-52.
69. Ogawa N, Hirose Y and Nomura M: Biochemical and functional aspects of neuropeptides and their receptors in aged rat brain.; in Recent Research on Neurotransmitter Receptors, Yoshida H eds, Excerpta Medica, Amsterdam (1986) pp56-68.
70. Beal MF, Mazurek M, Tran V, Chatta G, Bind E and Martin J: Reduced numbers of somatostain receptors in the cerebral cortex in Alzheimer's disease. Science (1985) 29, 289-291.
71. Bouras C, De St Hilaire-Kafi D and Constantinidis J: Neuropeptides in Alzheimer's disease: A review and morphological results. Prog NeuroPsychopharmacol Biol Psychiatry (1986) 10, 271-286.
72. Matsuoka N, Yamazaki M and Yamaguchi I: Changes in brain somatostain in memory-deficient rats: Comparison with cholinergic markers. Neuroscience (1995) 66, 617-626.
73. Tanaka K, Ogawa N, Asanuma M, Hirata H, Kondo Y, Chou H and Mori A: Effects of chronic codergocrine mesylate administration on the brain somatostatinergic system in aged rats. Arch Gerontol Geriatr (1992) 15, 133-139.
74. Dresse A, Marechal D, Scuvee- Moreau J and Seutin V: Towards a pharmacological approach of Alzheimer's disease based on the molecular biology of the amyloid precursor protein (APP). Life Sci (1994) 55, 2179-2187.
75. Goedert M: Molecular dissection of the neurofibrillary lesions of Alzheimer's diseane. Arzneim Forsch Drug Res (1995) 45, 403-409.
76. Lansbury PT: Consequences of the molecular mechanism of amyloid formation for the understanding of the pathogenesis of Alzheimer's disease and the development of therapeutic strategies. Arzneim Forsch/Drug Res (1995) 45, 432-434.
77. Masters CL and Beyreuther K: Molecular neuropathology of Alzheimer's disease. Arzneim Forsch Drug Res (1995) 45, 410-412.
78. Rogers J: Inflammation as a pathogenic mechanism in Alzheimer's disease. Arzneim Forsch Drug Res (1995) 45, 439-442.
79. Frölich L and Riederer P: Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Arzneim Forsch/Drug Res (1995) 45, 443-446.
80. Smith MA, Sayre LM, Monnier VM and Perry G: Radical AGEing in Alzheimer's disease. Trends Neurosci (1995) 18, 172-176.
81. Roth GS, Joseph JA and Mason RP: Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci (1995) 18, 203-206.
82. Hardy J, Adolfsson R, Alafuzoff I, Bucht G, Marcusson J, Nyberg P, Perdahl E, Wester P and Winblad B: Transmitter deficits in Alzheimer's disease. Neurochem Int (1985) 7, 545-563.
83. Bowen DM, Smith CB, White P and Davison AN: Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain (1976) 99, 459-496.
84. Whitehouss PJ, Price DL, Struble RG, Clark AW, Coyle JT and De Lony MR: Alzheimer's disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol (1981) 10, 122-126.
85. White P, Hiley CR, Goodhart MJ, Carrasco LH, Keet JP, Williams IEI and Bowen DM: Neocortical cholinergic neurons in elderly people Lancet (1977) i, 668-670.
86. Davies P and Verth AH: Regional distribution of muscarinic acetylcholine receptors in normal and Alzheimer's type dementia brains. Brain Res. (1978) 138, 385-392.
87. Rinne JO. Rinne JK, Laakso K, Paljarvi L and Rinne UK: Reduction in muscarinic receptor binding in limbic areas of Alzheimer brain. J Neurobiol Neurosurg Psychiatry (1984) 47, 651-652.
88. Reisine TD. Yamamura HI, Bird ED, Spokes E and Enna SJ: Pre and postsynaptic neurochemical alterations in Alzheimer's disease. Brain Res (1987) 159, 477-481.
89. Ogawa N, Mizukawa K, Asanuma M and Mori A: Abnormalities in muscarinic cholinergic receptors and their G-protein coupling systems in cerebral frontal cortex in Alzheimer's disease. Arch. Gerontol Geriatr (1993) 17, 77-89.
90. Ogawa N, Mizukawa K, Kada K, Yoshikawa K and Kanazawa I: Alterations in muscarinic cholinergic receptors and the second messenger system in the cerebral cortex in Alzheimer-type dementia; in Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Nagatsu T, Fisher A and Yoshida M eds, Plenum Press, New York (1990) pp553-558.
91. Griffiths PD, Perry RH and Crossman AR: A detailed anatomical analysis of neurotransimitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neurosci Lett (1994) 169, 68-72.
92. Pedigo NW: Neurotransmitter receptor plasticity in aging. Life Sci (1994) 55, 1985-1991.
93. Ehlert FJ: The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol Pharmacol (1985) 28, 410-421.
94. Olianas MC, Onali P, Neff NH and Costa E: Adenylate cyclase activity of synaptic membranes from rat striatum: Inhibition by muscarinic receptor agonists. Mol Pharmacol (1983) 23, 393-398.
95. Brown E, Kendal DA and Nahorski SR: Inositol phospholipid hydrolysis in rat cerebral cortical slices: I. Receptor characterisation. J Neurochem (1985) 42, 1379-1387.
96. Gonzalez RA and Crew FT: Cholinergic and adrenergic-stimulated inositide hydrolysis in brain: Interaction, regional distribution, and coupling mechanisms. J Neurochem (1985) 45, 1076-1084.
97. Jacobson MD, Wusteman M and Downes CP: Muscarinic receptors and hydrolysis of inositol phospholipids in rat cerebral cortex and parotid gland. J Neurochem (1985) 44, 465-472.
98. + channel. Nature (1985) 317, 536-538.
99. Boyd WD, Graham-White J, Blackwood G, Glen I and Mcqueen J: Clinical effects of choline in Alzheimer senile dementia. Lancet (1977) ii, 711.
100. Smith CM, Swash M, Exton-Smith AN, Phillips MJ, Overstall PW, Priper ME and Bailey MR: Choline therapy in Alzheimer's disease. Lancet (1978) ii, 318.
101. Muramoto O, Sugishita M, Sugita H and Toyokura Y: Effect of physostigmine on constructional and memory tasks in Alzheimer's disease. Arch Neurol (1979) 36, 501-503.
102. Summers WK, Majovski LV, Marsh GM, Tachiki K and Kling A: Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med (1986) 315, 1241-1245.
103. Pirozzolo FJ, Baski DJ, Swihart AA and Apple SH: Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer type. N Engl J Med (1987) 316, 1603.
104. Farlow M, Gracon JI, Hershey LA, Lewis KW, Jadowsky CH and Dolan-Ureno J: A controlled trial of tacrine in Alzheimer's disease. JAMA (1992) 268, 2523-2529.
105. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody RS and The Tacrine Collaborative Study Group: A double-blind placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med (1992) 327, 1253-1259.
106. Knapp MJ, Knopman DS, Soloman PR, Pendlebury WW, Davis CS and Gracon Sl: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA (1994) 271, 985-991.
107. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI and Lewis KW; Hepatotoxic effects of tacrine administration in patients with Alzheimer' s disease. JAMA (1994) 271, 992-998.
108. Kurz A, Marquard R and Mosch D: Tacrin: Ein Fortschritt in der Behandlung der Alzheimer-Krankheit? Z Gerontol Geriatr (1995) 28, 163-168.
109. Antuono PG: Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease: A double-blind, placebo-controlled study. Mentane Study Group. Arch. Intern. Med (1995) 155, 1766-1772.
110. al-Casey S, Brewster D, Viau C and Acosta D: Effect of glutathione depletion and oxidative stress on the in vitro cytotoxicity of velnacrine maleate. Toxicol Lett (1995) 76, 257-265.
111. Adem A, Mohammed AH, Winblad B and Henriksson BE: A novel cholinesterase THB013: Biochemical and behavioural studies. J Neural Transm Parkinson's Dis (1994) 81, 139-148.
112. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y and Yamatsu K: Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: Comparison with other inhibitors; in Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases. Vol 2. Nagatsu T, Fisher A and Yoshida M eds. Plenum Press, New York (1990) pp409-413.
113. Davis RE, Doyle PD, Carrol RT, Emmerling MR and Jaen J: Cholinergic therapies for Alzheimer's disease: Palliative or disease altering? Arzneim Forsch/Drug Res (1995) 45, 425-431.
114. Cereda E, Brambilla A, Ezhaya A, Gaida W, Mendia K, Monferini E, Pitsikas N, Schiavi GB and Sagrada A: Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders. Eur J Drug Metab Pharmacokinet (1994) 19, 179-183.
115. Cortes R, Probst A, Tobler HJ and Palacios JM: Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies. Brain Res (1986) 362, 239-253.
116. Ogawa N, Asanuma M, Mizukawa K, Hirata H, Chou H and Mori A: Post-ischemic administration qf bifemelane hydrochloride prohibits ischemia-induced depletion of the muscarinic M1-receptor and its mRNA in gerbil hippocampus. Brain Res (1992) 591, 171-175.
117. Games D, Adams D, Alessandrini R, Berthelete P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B and Zhao J: Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature (1995) 373, 523-527.
118. Gottfries CG: Therapy options in Alzheimer's disease. Br J Clin Pract (1994) 48, 327-230.
119. Hellweg R: Trophic factors during normal brain aging and after functional damage. J Neural Transm-Gen Soct (1994) 44, 209-217.
120. Emerich DF, Winn SR, Harper J, Hammang JP, Baetge EE and Kordower JH: Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: Rescue and sprouting of degenerating cholinergic basal forebrain neurons. J Comp Neurol (1994) 349, 148 -164.
121. Scott SA and Crutcher KA: Nerve growth factor and Alzheimer's disease. Rev Neurosci (1994) 5, 179-211.
122. Svennerholm L: Gangliosides: A new therapeutic agent against stroke and Alzheimer's disease. Life Sci (1994) 55, 2125-2134.
123. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y and Hagino N: Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia (1995) 6, 99-107.
124. Simpkins JW, Singh M and Bishop J: The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging (1994) 15, S195-197.
125. Mondadori C: In search of the mechanism of action of the nootropics: New insights and potential clinical implications. Life Sci (1994) 55, 2171-2178.
126. Ban TA: Psychopharmacology and successful cerebral aging. Prog Neuropsychopharmacol Biol Psychiatry (1995) 19, 1-9.
127. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F and Billardon M: Long term and high-dose piracetam treatment of Alzheimer's disease. Neurology (1993) 43, 301-305.
128. Lee CR and Benfield P: Aniracetam: An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders. Drugs Aging (1994) 4, 257-273.
129. Ruther E, Ritter R, Apecechea M, Freytag S and Windisch M: Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry (1994) 27, 32-40.
130. Ingram DK, Joseph JA, Spangler EL, Roberts D, Hengemihle J and Fanelli RJ: Chronic nimodipine treatment in aged rats: Analysis of motor and cognitive effects and muscarinic-induced striatal dopamine release. Neurobiol Aging (1994)15, 55-61.
131. Sudilovsky A, Cutler NR, Sramek JJ, Wardle T, Veroff AE, Mickelson W, Markowitz J and Repetti S: A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer's disease. Alzheimer Dis Assoc Disord (1993) 7, 105-111.
132. Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM and Chase TN: D-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord (1994) 8, 198-205.
133. Cutler NR, Fakouhi D, Smith WT, Hendrie HC, Matsuo F, Sramek JJ and Herting RL: Evaluation of multiple doses of milacemide in the treatment of senile dementia of the Alzheimer Type. J Geriatr Psychiatry Neurol (1993) 6, 115-119.
134. Heuser I, Heuser-Link M, Gotthardt U, Grasser A and Holsboer F: Behavioral effects of a synthetic corticotropin 4-9 analog in patients with depression and patients with Alzheimer's disease. J Clin Psychopharmacol (1993) 13, 171-174.
135. Rogers J, Kirby LC, Hempelman SR, Berry DI, McGeer PL, Kazniak A, Zalinski W, Cofild J, Mansukhani L, Willson P and Kogan F: Clinical trial of indomethacinin in Alzheimer's disease. Neurology (1993) 43, 1609-1611.
136. Halliwell B, Hoult JR and Black DR: Oxidants, inflammation, and antiinflammatory drugs. FASEB Fed Am Soc Exp Biol J (1988) 2, 2867 -2873.
137. Dowson JH, Mountjoy CQ, Cairns MR and Wilton CH.: Changes in intraneuronal lipopigment in Alzheimer's disease. Neurobiol Aging (1992) 13, 493-500.
138. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC and Cayley ACD: Plasma concentration of vitamins A and E and carotenoids in Alzheimer's disease. Age Aging (1992) 21, 91-94.
139. Clausen J, Nielson SA and Kristensen M: Biochemical and clinical effects of an antioxidative supplementation of geriatric patients: A double-blind study. Biol Trace Elem Res (1989) 20, 135-151.
140. McLachlan DRC, Dalton AJ, Kruck TPA, Bell MY, Smith WL, Kaloow W and Andrews DF: Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet (1991) 337, 1304-1308.
141. Hall ED: Lazeroids: Efficacy and anti-oxidant mechanism in experimental cerebral ischemia; in Pharmacology of Cerebral Ischemia, Krieglstein J and Oberpichler H eds, Wissenchaftliche Verlagsgesellschaft mbH, Stuttgart (1990) pp345-350.
142. Carney JM, Starke-Reed PE, Oliver CN, Landum RW, Cheng MS, Wu JF and Floyd RA: Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-a-phenylnitrone. Proc Natl Acad sci USA (1991) 88, 3633-3636.
143. Hamada H, Hiramatsu M, Edamatsu R and Mori A: Free radical scavenging action of baicalein. Arch Biochem Biophys (1993) 306, 261-266.
144. Ogawa N: Alzheimer type dementia; in Brain Receptors: New Edition, Ogawa N ed, Sekai Hoken Tsushinsha, Osaka (1989) pp524-533.
145. Rossor MN, Iversen LL, Mountjoy CQ, Roth M, Hawthorn J, Ang VY and Jenkins JS: Arginine vasopressin and, choline acetyltransferase in brains of patients with Alzheimer type senile dementia. Lancet (1980) ii, 1367.
146. Smith CJ, Perry EK, Perry RH, Candy JM, Johnson M, Bonham JR, Dick DJ, Fairbairn A, Blessed G and Birdsall NJM: Muscarinic cholinergic receptor subtypes in hippocampus in human cognitive disorders. J Neurochem (1988) 50, 847-856.
147. Zilles KMQ, Schleicher A, Schroeter M, Kramer M and Wittle O: Plasticity and neurotransmitter receptor changes in Alzheimer's disease and experimental cortical infarcts. Arzneim Forsch/Drug Res (1995) 45, 361-366.
148. Gottfries CG: Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment. Psychopharmacology (1985) 86, 245-252.